Thus, this work supports the idea that the blockade of KCa3.1 channels, alone or in combination with other treatments, can be exploited to reduce inflammation, fibrosis and muscle damage in muscular dystrophy. This evidence concerns the gene KCNN4 and muscular dystrophy.